Rebecca Nofsinger
Overview
Explore the profile of Rebecca Nofsinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
73
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gleeson J, Zhang S, Subelzu N, Ling J, Nissley B, Ong W, et al.
Mol Pharm
. 2024 Jun;
21(8):3880-3888.
PMID: 38941485
Oral delivery of potent peptide drugs provides key formulation challenges in the pharmaceutical industry: stability, solubility, and permeability. Intestinal permeation enhancers (PEs) can overcome the low oral bioavailability by improving...
2.
Yang W, Lipert M, Nofsinger R
Drug Discov Today
. 2023 Jun;
28(9):103685.
PMID: 37356613
A drug's permeability across biological membranes is a key property associated with the successful development of an orally absorbed drug candidate. Although a variety of methods are available for predicting...
3.
Johnson A, Ballard J, Leithead A, Miller C, Faassen F, Zang X, et al.
Pharm Res
. 2023 Jan;
40(7):1641-1656.
PMID: 36720831
Administration of long-acting injectable suspensions is an increasingly common approach to increasing patient compliance and improving therapeutic efficacy through less frequent dosing. While several long-acting suspensions have recently been marketed,...
4.
Brigham N, Nofsinger R, Luo X, Dreger N, Abel A, Gustafson T, et al.
J Control Release
. 2020 Dec;
329:316-327.
PMID: 33278481
Medical prescriptions for the alleviation of post-surgical pain are the most abundant source of opioids in circulation. As a systemic drug delivery source, opioids leave patients at high risk for...
5.
Gadgil P, Alleyne C, Feng K, Hu M, Gindy M, Buevich A, et al.
Pharm Res
. 2019 Aug;
36(10):151.
PMID: 31451949
Purpose: In this study we evaluated the utility of in-vitro screening tools for predicting the in-vivo behavior of six cyclic peptides with different solubility and permeability properties (BCS class II...
6.
Smith D, Kapoor Y, Hermans A, Nofsinger R, Kesisoglou F, Gustafson T, et al.
Int J Pharm
. 2018 Sep;
550(1-2):418-428.
PMID: 30172750
Drug development is a long process which requires careful evaluation of the drug substance (active pharmaceutical ingredient, API), drug product (tablet, capsule etc.) and the bioperformance (both pre-clinical and clinical)...
7.
Daublain P, Feng K, Altman M, Martin I, Mukherjee S, Nofsinger R, et al.
Mol Pharm
. 2017 Mar;
14(5):1634-1645.
PMID: 28329443
The purpose of this research was to assess variability in pharmacokinetic profiles (PK variability) in preclinical species and identify the risk factors associated with the properties of a drug molecule...
8.
Walsh P, Stellabott J, Nofsinger R, Xu W, Levorse D, Galipeau K, et al.
AAPS PharmSciTech
. 2016 Sep;
18(4):1408-1416.
PMID: 27600321
Despite many documented differences in gut physiology compared to humans, the beagle dog has been successfully used as a preclinical model for assessing the relative bioavailability of dosage forms during...
9.
Walsh P, Bothe J, Bhardwaj S, Hu M, Nofsinger R, Xia B, et al.
Drug Dev Ind Pharm
. 2015 Sep;
42(5):836-44.
PMID: 26339722
Preclinical species are a crucial component of drug development, but critical differences in physiology and anatomy need to be taken into account when attempting to extrapolate to humans or between...
10.
Walji A, Sanchez R, Clas S, Nofsinger R, de Lera Ruiz M, Li J, et al.
ChemMedChem
. 2014 Dec;
10(2):245-52.
PMID: 25469982
Developing new antiretroviral therapies for HIV-1 infection with potential for less frequent dosing represents an important goal within drug discovery. Herein, we present the discovery of ethyl (1-((4-((4-fluorobenzyl)carbamoyl)-1-methyl-2-(2-(5-methyl- 1,3,4-oxadiazole-2-carboxamido)propan-2-yl)-6-oxo-1,6-dihydropyrimidin-5-yl)oxy)ethyl) carbonate...